A recent study indicated that Lectin-type oxidized LDL receptor-1 (LOX-1) was a distinct surface marker for human polymorphisms myeloid-derived suppressor cells (PMN-MDSC). The present study was aimed to investigate the existence LOX-1 PMN-MDSC in hepatocellular carcinoma (HCC) patients. One hundred and twenty-seven HCC patients, 10 patients with mild active chronic hepatitis B, 10 liver cirrhosis due to hepatitis B, 10 liver dysplastic node with hepatitis B and 50 health control were included. 
Summary
A recent study indicated that Lectin-type oxidized LDL receptor-1 (LOX-1) was a distinct surface marker for human polymorphisms myeloid-derived suppressor cells (PMN-MDSC). The present study was aimed to investigate the existence LOX-1 PMN-MDSC in hepatocellular carcinoma (HCC) patients. One hundred and twenty-seven HCC patients, 10 patients with mild active chronic hepatitis B, 10 liver cirrhosis due to hepatitis B, 10 liver dysplastic node with hepatitis B and 50 health control were included. 
Introduction
Myeloid-derived suppressor cells (MDSC) have been suggested to be a novel target for many malignant diseases, 1 including hepatocellular carcinoma (HCC). [2] [3] [4] [5] However, target agents on MDSC have not displayed promising efficacy for HCC patients. 6 One of the critical reasons is the heterogeneity of MDSC testing among different centres. [2] [3] [4] [5] 7 At present, the standard method to separate MDSC is by density gradient centrifugation only in peripheral blood (PB). 7, 8 This testing technology is not easily standardized between laboratories, which might be a critical cause of the heterogeneity of results in MDSCtargeted studies. Thus, a method that is more easily standardized between laboratories is needed to pave the way to the clinical usage of MDSC-targeted therapy.
Another critical issue for MDSC-targeted therapy is the shortage of specific surface markers to separate MDSC from neutrophils. A recent study indicated that lectin-type oxidized LDL receptor-1 (LOX-1) is a distinct surface marker for human MDSC, which is the first novel marker for polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). 7 Also, the LOX-1 + PMN-MDSCs were tested in whole blood (WB), which made the procedure easier in practical terms to be standardized between laboratories.
In the present study we investigated the existence of LOX-1 PMN-MDSC in HCC patients, their latent mechanism and their association with clinical parameters.
Methods

Patients and healthy donors
During the period between June 2016 and September 2016, we investigated a series of 127 HCC patients before anticancer treatment, 10 patients with mild active chronic hepatitis B (alanine aminotransferase above twice the upper limit of normal without liver failure), 10 patients with liver cirrhosis due to hepatitis B and 10 patients with liver dysplastic node with hepatitis B in the Third Affiliated Hospital of Guangzhou Medical University and the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. The diagnosis of HCC was confirmed by pathology or the American Association for the Study of Liver Diseases radiological criteria by either computed tomography (CT) or magnetic resonance imaging (MRI). Age-and gendermatched healthy controls (n = 50) consisted of local volunteers. All patients and healthy controls were also screened for serum human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, hepatitis D virus (HDV) antigen and HDV antibody. Patients and healthy controls who were positive for HIV, chronic hepatitis virus infection (except for hepatitis B virus) and other acute infections (including pneumonia, urinary tract infection, etc.) who were pregnant, patients who received systematic corticosteroids, immnunosuppressive agents or anticancer therapies and those with fever were excluded from this study. This study was approved by the Clinical Ethics Review Board of the Third Affiliated Hospital of Guangzhou Medical University and the Third Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from all patients at the time of admission.
Peripheral blood mononuclear cells (PBMC) isolation and flow cytometric analysis
Blood samples were analysed within 6 hr after sampling. PBMCs were isolated from WB by Ficoll centrifugation. The following antihuman antibodies were purchased from eBioscience (San Diego, CA): CD11b-fluorescein isothiocyanate (FITC), human leucocyte antigen D-related-phycoerythrin (HLA-DR-PE), CD14-PE-cyanin 7 (Cy7), CD15-eFluor450, LOX-1-allophycocyanin (APC) and their corresponding isotype controls. The cell phenotypes were analysed by flow cytometry on a flow cytometric fluorescence-activated cell sorter (FACS)Aria II flow cytometer (BD Bioscience, San Jose, CA, USA), and data were analysed with FlowJo version 10.0.7 (FlowJo, Treestar, Inc., San Carlos, CA). For the flow cytometric sorting, a BD FACSAria cell sorter (BD Bioscience, San Jose, CA, USA) was used. The strategy for MDSC sorting was: LOX-1 + CD15 + for PMN-MDSCs and LOX-1 À CD15 + for PMNs from alive WB cells.
T-cell proliferation and activation assay
T-cell proliferation was determined by 5,6-carboxyfluorescein diacetate, succinimidyl ester (CFSE) dilution. Purified T cells were stained with CFSE (3 lM; Invitrogen, Carlsbad, CA), stimulated with 0Á5 lg/ml 3-hr precoated anti-CD3 and 0Á5 lg/ml anti-CD28 (eBioscience), and cultured alone or cocultured with autologous PMN-MDSCs/PMNs at the indicated ratios for 72 hr. The cells were then labelled for surface marker expression with CD4-PE or CD8-PE-Cy5 antibodies, and T-cell proliferation was analysed on a flow cytometer. 
Measurement of intracellular ROS
ROS measurements were determined using the 2 0 ,7 0 -dichlorofluorescein diacetate (DCFDA) stain. Briefly, WB were incubated with 2Á5 lM DCFDA at 37°for 30 min after red blood cell lysis. Cells were then washed and resuspended in phosphate-buffered saline (PBS), stained with CD15-eFluor450 and LOX-1-APC at 4°for 30 min. ROS was analysed using flow cytometer with excitation and emission wavelengths of 490 and 520 nm, respectively, in LOX-1 + CD15 + cells and LOX-1 À CD15 + cells.
Enzyme-linked immunosorbent assay (ELISA)
Culture supernatants of the T cell and MDSC co-culture system were collected for ELISA testing. Interferon (IFN)-c quantification in culture supernatants was determined using an ELISA following the manufacturer's instructions (DKW12-1000-09; Dakewe Bioengineering Co., Shenzhen, Guangdong).
Arginase activity assay
The arginase activity was measured in cell lysates. Briefly, cells were lysed with 0Á1% Triton X-100 for 30 min, then 25 mM Tris-HCl and 10 mM MnCl 2 was added. The enzyme was activated by heating at 56°for 10 min. Arginine hydrolysis was performed by incubating the lysate with 0Á5 M L-arginine for 120 min at 37°. After the addition of a-isonitrosopropiophenone (dissolved in 100% ethanol), the urea concentration was measured at 540 nm, followed by heating at 95°for 30 min.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
RNA was extracted with a multisource total RNA miniprep kit (AXYGEN Biosciences, Hangzhou, China) and qRT-PCR was performed utilizing commercially available primers (Supporting information, Table S2 ) and SYBR Premix Ex Taq II (Code, DRR081; Takara Biotechnology (Dalian) Co., Ltd, Dalian, China). Fluorescence for each cycle was quantitatively analysed using the ABI Prism 7000 sequence detection system (Life Technologies, Gaithersburg, MD). The results were reported as relative expression, normalized with the b-actin housekeeping gene as endogenous control and expressed in arbitrary units (primers used are shown in Supporting information, Table S1 ).
ChIP assay
The chromatin immunoprecipitation (ChIP) assay was performed following the instructions from Millipore (Billerica, MA). In brief, LOX-1 + CD15 + PMN-MDSCs were fixed with a 1% formaldehyde solution, lysed and sheared by sonication. Cell lysates were precleared with protein G-agarose and immunoprecipitated with specific antibodies or an anti-immunoglobulin (Ig)G control. Antibody-chromatin complexes were collected with protein Gagarose. The DNA in the complex was recovered and quantitated by qPCR. Ten per cent of the lysate before immunoprecipitation was used as the input control. Amplification of cyclophilin from the input was used as a loading control. For sequential ChIP assays, samples were immunoprecipitated with anti-XBP1 antibody (619502, Biolegend, San Diego, CA, USA). DNA from both rounds of ChIP assays was purified and subjected to qPCR (primers used are shown in Supporting information, Table S1 ).
Immunohistochemistry (IHC)
HCC tissues were sectioned at 4-lm thickness, dewaxed with xylene, rehydrated with graded ethanol and immersed in sodium citrate (pH 6Á0) for antigen retrieval using a microwave. IHC was conducted according to the manufacturer's protocol [ab210059 DoubleStain IHC Kit: M&R on human tissue, diaminobenzidine (DAB) & AP/ Red, abcam, Cambridge, MA] Slides were incubated in blocking reagent; rabbit [anti-LOX 1 antibody ab126538, abcam, Cambridge, MA) and mouse [anti-CD15 antibody (FUT4/815) bovine serum albumin (BSA)] and azide-free ab212396, abcam, Cambridge, MA) primary antibody mixture were used to cover the tissue and incubated. Rabbit AP polymer and mouse HRP polymer were added and incubated. DAB working solution was applied to completely cover the tissue and incubated. Then, Permanent Red working solution was added and incubated and counterstained with haematoxylin and incubated, washing between steps with PBS-T. Aqueous mounting medium was added horizontally in an oven at 40-50°for at least 30 min until the slides were thoroughly dried.
Two pathologists, who were blinded to the clinicopathological and follow-up information, evaluated IHC staining independently. Visible brown staining was considered to indicate positive staining for CD15 with red for LOX-1. Double-positive cells were counted in each mm 2 .
Western blotting
Lysates from LOX-1 + CD15 + PMN-MDSCs and LOX-1 À CD15 + PMN containing 100 lg protein were incubated with 2 lg of antibodies against interested proteins (rabbit monoclonal to XBP1, ab109221, abcam; rabbit monoclonal to activating transcription factor 3 (ATF3), ab 207434, abcam; mouse monoclonal to DDIT3, ab11419, abcam) for 18 hr at 4°, followed by incubation with protein A/G agarose for 1 hr at 4°. The immunoprecipitates were then washed with PBS and heated at 95°f or 5 min, followed by centrifugation at 5000 g for 1 min. The supernatants were then subjected to Western blotting analysis. Briefly, target molecules were detected using specific primary antibodies and horseradish peroxidase (HRP)-conjugated secondary antibodies, followed by detection using an enhanced chemiluminescence (ECL) HRP chemiluminescent substrate reagent kit (Invitrogen).
RNA-sequencing data analysis
LOX-1 + CD15 + PMN-MDSCs and LOX-1 À CD15 + PMN from HCC patients were enriched by CD15b-beads and then sorted on a FACSAria cell sorter (BD Bioscience). The sorting purity was > 95%. RNA sequencing was performing using Illumina Hiseq 2500 platform (Illumina, San Diego, CA). A VAHTS total RNA-Seq library preparation kit (Vazyme Biotech Co., Ltd, China) was used for library preparation. Single-end read runs were used, with read lengths up to 50 base pairs (bp) in high output mode, 20 M total read counts. Data were aligned using RSEM version 1.2.12 software against 10-mm genome and gene-level read counts and reads per kilobase of transcript per million mapped reads (RPKM) values at gene level were estimated for ensemble transcriptome. Samples with at least 80% aligned reads were analysed. DESeq2 was used to estimate the significance between any two experimental groups. Overall changes were considered significant if they passed false discovery rate (FDR) < 5% thresholds, with an additional threshold on fold change (fold > 1Á2) taken to generate the final gene set.
Patient follow-up and statistical analysis
Patients returned for follow-up appointments at least every 2 weeks during the first 6 months, and then every month thereafter until death. The follow-up duration was calculated from the first day of therapy to the day of death or to the last examination. Overall survival (OS) was the end-point, which was calculated from the first day of treatment to death.
Variables in different groups were compared using the v² test (or Fisher's exact test, if indicated) and t-test or non-parametric Mann-Whitney U-tests. OS was calculated using the Kaplan-Meier method, and the differences were compared using the log-rank test. The criterion for statistical significance was set at a = 0Á05 and all P-values were based on two-sided tests. For in-vitro experiments, statistical analyses were performed using paired t-tests. Correlations between different parameters were analysed using a Spearman's rank test. Statistical tests were performed using GraphPad PRISM version 5.0a and SPSS Statistics 20.0 (SPSS, Chicago, Illinois). P values of 0Á05 were considered significant.
Results
LOX-1 + CD15 + PMN-MDSC expansion in HCC patients
During the period between June 2016 and September 2017, we investigated a series of HCC patients before anticancer treatment (n = 127), patients with mild active chronic hepatitis B (n = 10), liver cirrhosis due to hepatitis B (n = 10) and liver dysplastic node with hepatitis B (n = 10) in two centre hospitals. Age-and gender-matched healthy controls (n = 50) consisted of local volunteers. Blood samples were collected at the disease diagnosis. Peripheral blood mononuclear cells (PBMCs) were isolated from WB by Ficoll centrifugation and analysed within 6 hr after blood sampling. Circulating frequencies of PMNMDSCs in PBMC were defined by classic markers (CD11b + CD14 À HLA-DR À/low CD15 + ). 9 LOX-1 + CD15
+ PMN-MDSC were tested both in WB 7 ( Fig. 1a) and PBMC (Fig. 1b) (Fig. 1c) . Notably, PBMC was used to enrich MDSC; thus, LOX-1 + CD15 + PMN-MDSC should be more abundant in PBMC than WB. We found that LOX-1 + CD15 + PMN-MDSC were much more abundant in PBMC than in WB (Fig. 1d ) Then, in order to illustrate the association of LOX-1 + CD15 + PMN-MDSC in circulation and tumour tissues, IHC were utilized to test the LOX-1 + CD15 + PMN-MDSC. The density of LOX-1 + CD15 + PMN-MDSC in tumour tissue was positively related to that in circulation (Fig. 1e) .
LOX-1 + CD15 + PMN-MDSCs suppressed T-cell activation
Suppressive ability to T-cell proliferation was the key characteristic of MDSC. In order to confirm the immune suppressive capacity of LOX- (Fig. 2) .
Production of ROS and activation of arginase I were the mechanism for LOX-1 + CD15 + PMN-MDSCmediated immune suppression Based on the finding that LOX-1 + CD15 + PMN-MDSCs from HCC patients suppressed antigen non-specific T-cell proliferation, we further explored the underlying mechanisms controlling LOX-1 + CD15 + PMN-MDSCmediated T-cell suppression. Previous reports have confirmed that arginase I or ROS were immune mediators for PMN-MDSC-mediated immune suppression. 9 Thus, arginase inhibitor nor-NOHA, L-arginine supplementation or N-acetyl-L-cysteine (NAC), a ROS inhibitor, were utilized to reverse the suppressive effects of LOX-1 + CD15 + PMN-MDSCs on T-cell proliferation in the coculture system. 10 As a result, the suppression of T-cell proliferation and IFN-c production was reversed by ROS inhibitor NAC, nor-HOHA and L-arginine (Fig. 3a) . We then investigated the ROS level of LOX-1 + CD15 + PMN by DCFDA, which indicated that the ROS levels were higher in HCC-related LOX-1 + CD15 + PMN-MDSCs than LOX-1 À CD15 + PMNs. Also, the mRNA levels of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase NOX2, the key protein complex responsible for ROS production in MDSCs, were higher in LOX-1 + CD15 + PMN-MDSC (Fig. 3b) . Meanwhile, the expression of arginase I and activity of arginase were also significantly raised in HCC related LOX-1 + CD15 + PMNMDSCs compared with LOX-1 À CD15 + PMNs (Fig. 3c ).
Endoplasmic reticulum (ER) stress mediated LOX-1 expression and suppressive function of LOX-1 + CD15 + PMN-MDSCs
In order to test the molecular mechanism of HCC related LOX-1 + CD15 + PMN-MDSCs, LOX-1 + CD15 + PMN-MDSCs and LOX-1 À CD15 + PMN-MDSCs were sorted from the same patients and whole transcriptome analysis was performed using RNA-seq. A total of 124 genes were significantly different with P < 0Á01 and HR > 1Á2 or < 0Á8 (Fig. 4a) . Cellular component analysis reveals that the intrinsic component of membrane, intracellular membrane-bound organelle, was the most changed field (Fig. 4b) . Molecular function analysis revealed that binding function, including nucleic acid binding, presented the most altered genes (Fig. 4c) . Combination analysis of the molecular function and cell component, the XBP1, a hallmarker for ER stress, was the most potential mechanism for HCC-related LOX- (Fig. 4d,e) . Meanwhile, the expression of ATF3 and CCAAT/enhancer binding protein (CHOP) was also higher in LOX-1 + PMN-MDSC tested by qRT-PCR with negative Western blot tests (Fig. 4d,e) . Furthermore, we utilized ER stress inducer thapsigargin (THG) to induce the expression of LOX-1 and suppressive function in CD15 + PMN from healthy donors with or without the inhibitor of XBP1, B-I09. As a result, THG-induced LOX-1 expression among CD15 + PMN and THG-induced LOX-1 + CD15 + PMN-MDSCs presented a suppressive capability to T-cell proliferation. The efficacy of THG was abrogated by B-I09 (Fig. 5a) . In order to investigate whether XBP1 regulated the promoter of LOX-1, we found the potential binding site of XBP1 in the LOX-1 promoter region (Fig. 5b) . However, ChIP analysis revealed that XBP1 does not bind to the LOX-1 promoter (Fig. 5c ). Tumour-conditioned media of HCC cell lines (Hu7, HepG2, 97L) and serum of HCC patients with increased LOX-1 + CD15 + PMN-MDSCs were used to induce LOX-1 and XBP1 expression in CD15 + PMN from healthy donors. However, HCC tumour cells (TCM) and HCC serum did not increase the LOX-1 and XBP1 expression significantly, compared with controls (Fig. 5d) . Above all, ER stress mediated LOX-1 expression and the suppressive function of LOX-1 + CD15 + PMNMDSCs. Fig. 6a and Supporting information, Table S2 ). Patients were then divided into two parts according to LOX-1 + CD15 + PMNMDSCs level. Patients with low levels of LOX-1 + CD15 + PMN-MDSCs presented better overall survival (Fig. 6b) .
Discussion
MDSC has been confirmed to be a critical mediator for immune tolerance to multiple malignances and presents promising clinical usage by basic researches and clinical investigations.
9,14-16 Many drugs were found to eliminate C6orf223  ACY1  PRH1  TEAP2E  FGF2  NHLRC4  QTRT1  OCDC151  AWDR36  FBXL22  HAS3  DUS3L  TBC1D8B  OCRL2  TMEM150A   TMEM255A  C8orf82  ANO8  ISOC2  HSD11B1L  DUSP28  TRIM7  MRPL33  FABP5  HIST1H2BH  CORO6  STEAP3  SNRPA1  C11orf95  PAQR7  MRPL24  VGLL4  AP4M1  DBF4B  SIGLEC11  NDUFB9  ASCL2  ZFP41  UBE2Q2  SLC26A6  BAIAP2L1  NUP160  WRAP73  FDPS  QPCTL  ACAD8  STK11  TMEM9B  ALX3  PCBD2  FKRP  PDXK  CRY2  FRL3  FBXW4  AKAP1  BPNT1  PPP2R5B  GOT1  KAT5  PRRT3  PLAGL2  SNRPB  RASSF1  TRMT61A  DPH7  XBP1  TOP3B  HDAC3  DNAJC9  RRNAD1  OGG1  TMED1  SLC30A5  PARP3  RPS19BP1  CMC4  SPAG7  SLC30A5  PARP3  RPS19BP1  CMC4  SPAG7  SLC27A3  MCEMP1  DNAJC14  ZNRF1  TMEM44  FAM132A  TRABD2A  VRTN  IGSF9  ACVR2B  CDH6  SDC2  KLC  ANKRD65  LDOC1  UNC13A  RAB30  GLI2  PCDH9  UGT3A1  SMIM24  CD79A  MS4A1  QR2W3  AHSP  ALAS2  HBM  HBG2  PAX5  PRTN3  TSPO2  HBD  TNFRSF13C  KIFRSF13C  UBD  RFPL3  CPNE4  AQP1 6, 18 One of the critical causes was the issue of testing MDSC by density gradient centrifugation, which was not a technique that was standardized easily by different laboratory. 7 Density gradient centrifugation needs strict controls on time, temperature, Ficoll density and other steps. 8 Different protocols between laboratories caused heterogenicity of the results. Thus, it is necessary to develop a method that is easily standardized. Lox-1 + was the first specific marker for human PMN-MDSC in lung cancer and head and neck cancer patients. 7 PMN-MDSC is the major subtype of MDSC, which means that PMN-MDSC can be tested in WB by flow cytometry. Flow cytometry testing is a potential diagnostic technique which is used in multiple diseases, especially leukaemia. Testing Lox-1 + CD15 + PMN- 
Supporting Information
Additional Supporting Information may be found in the online version of this article: Table S1 . Primers used. 
